#1-89E. A New Oral Option for Obesity? Oral Semaglutide 25 mg (The New England Journal of Medicine, 2025)

For patients with obesity who are hesitant about injectables, what effective oral alternatives can we offer? This episode delves into the OASIS 4 trial, which evaluated the efficacy and safety of once-daily oral semaglutide 25 mg. This randomized controlled trial demonstrated that in adults with overweight or obesity, oral semaglutide led to a superior mean body weight reduction compared to placebo over 64 weeks. The key finding is a clinically meaningful mean weight loss of 13.6%, positioning it as a potent non-injectable option that could enhance treatment flexibility and access. However, the study population was predominantly female and White, so caution is warranted when generalizing these results.

Reference: WHARTON, Sean, et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. The New England Journal of Medicine. 2025, 393(11), pp. 1077-1087. DOI: 10.1056/NEJMoa2500969

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original publication for detailed information.